Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$3.06 - $5.58 $28,506 - $51,983
-9,316 Reduced 1.89%
484,443 $1.6 Billion
Q1 2024

May 15, 2024

BUY
$2.03 - $6.59 $1 Million - $3.25 Million
493,759 New
493,759 $2.1 Billion

Others Institutions Holding PYXS

About Pyxis Oncology, Inc.


  • Ticker PYXS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 35,096,400
  • Market Cap $69.8M
  • Description
  • Pyxis Oncology, Inc., a preclinical stage biopharmaceutical company, engages in the development of therapies to treat cancers. Its immune-oncology product candidates include PYX-106, an investigational fully human immunoglobulin G1 isotype siglec-15 targeting antibody for the treatment of thyroid cancer, head and neck squamous cell carcinoma, no...
More about PYXS
Track This Portfolio

Track Superstring Capital Management LP Portfolio

Follow Superstring Capital Management LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Superstring Capital Management LP, based on Form 13F filings with the SEC.

News

Stay updated on Superstring Capital Management LP with notifications on news.